The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants.

MLA

Wang, Hong, et al. “The Novel Indomethacin Derivative CZ-212-3 Exerts Antitumor Effects on Castration-Resistant Prostate Cancer by Degrading Androgen Receptor and Its Variants.” Acta Pharmacologica Sinica, vol. 43, no. 4, Apr. 2022, pp. 1024–32. EBSCOhost, https://doi.org/10.1038/s41401-021-00738-w.

APA

Wang, H., Chang, Z., Cai, G., Yang, P., Chen, J.-H., Yang, S.-S., Guo, Y.-F., Wang, M.-Y., Zheng, X.-H., Lei, J.-P., Liu, P.-Q., Zhao, D.-P., & Wang, J.-J. (2022). The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants. Acta Pharmacologica Sinica, 43(4), 1024–1032. https://doi.org/10.1038/s41401-021-00738-w

Chicago

Wang, Hong, Zhe Chang, Guo-di Cai, Ping Yang, Jiang-He Chen, Shan-Shu Yang, Yin-Feng Guo, et al. 2022. “The Novel Indomethacin Derivative CZ-212-3 Exerts Antitumor Effects on Castration-Resistant Prostate Cancer by Degrading Androgen Receptor and Its Variants.” Acta Pharmacologica Sinica 43 (4): 1024–32. doi:10.1038/s41401-021-00738-w.